NCT03601338

Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths

Second Generation Low Molecular Weight Heparin (Bemiparin) as a Prophylactic for Management of Subsequent Pregnancy After an Unexplained Stillbirth: A Clinical Comparative Study

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: Hawler Medical University · Academic / Other
• Sex: Female
• Age: 18 Years – 44 Years
• Healthy volunteers: Accepted

Summary

Bemiparin for pregnant women with abnormal umbilical artery Doppler ultrasound

Detailed description

152 women with history of unexplained stillbirths were identified , umbilical arty Doppler ultrasound was conducted for them at 20-22 weeks gestation . they were divided into two group , group one are those with abnormal resistant index (= or more than 0.6) thy received Bemiparin 2500 IU subcutaneously daily up to 24 hours before delivery . Group 2 with normal umbilical artery resistant index received no any interventions just routine antenatal follow up .

Conditions

• Unexplained Stillbirth

Interventions

Type	Name	Description
DRUG	Bemiparin	second generation low molecular weight Heparin
OTHER	multivitamins and routine antenatal follow up	multivitamins and routine antenatal follow up

Timeline

• Start date: 2015-08-01
• Primary completion: 2018-12-01
• Completion: 2018-12-06
• First posted: 2018-07-26
• Last updated: 2018-12-10

Locations

1 site across 1 country: Iraq